Impact of p16-overexpression on overall and progression-free survival outcomes in oral cavity squamous cell carcinomas: A semi-national, population-based study.
Human papillomavirus
Oral cancer
Oral cavity cancer
P16
Prognostic biomarker
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
12
08
2020
accepted:
26
09
2020
pubmed:
18
10
2020
medline:
18
9
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
Human papillomavirus infection and p16-overexpression is a principal cause and favorable prognostic factor for oropharyngeal squamous cell carcinomas but the value as prognostic marker in oral cavity squamous cell carcinomas (OSCC) is undetermined. All patients diagnosed with OSCC in Eastern Denmark in the period 2008-2014 were enrolled. Survival estimates were evaluated as overall survival (OS) and progression free survival (PFS) by Kaplan-Meier survival curves and multivariate Cox-regression analyses. We included 575 patients from which 13% (n = 69) had p16-positive tumors. The 5-year OS were 55% and 62% for the p16-negative and p16-positive patients, respectively, and the 5-year PFS were 48% and 50%. In a multivariate survival analysis, p16-positivity showed no significant influence on OS (HR: 1.06 [0.67-1.70], p = 0.79) and PFS (HR: 1.11 [0.76-1.63], p = 0.58). In this population-based cohort of non-selected OSCC patients, we found no difference in survival outcomes when stratified on p16-overexpression status.
Identifiants
pubmed: 33069060
pii: S1368-8375(20)30467-X
doi: 10.1016/j.oraloncology.2020.105031
pii:
doi:
Substances chimiques
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105031Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.